1-(8-nonenyl)-3,7-dimethylxanthine | 156918-55-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 1-(8-nonenyl)-3,7-dimethylxanthine
• 英文别名: N-(8'-nonenyl)-3,7dimethylxanthine；1-(8-nonene)-3,7-dimethylxanthine；3,7-dimethyl-1-non-8-enylpurine-2,6-dione
• CAS: 156918-55-7
• 化学式: C₁₆H₂₄N₄O₂
• 分子量: 304.392
• InChiKey: IPQJHACDCLKERB-UHFFFAOYSA-N

物化性质

• 沸点：
  498.0±47.0 °C(Predicted)
• 密度：
  1.16±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  22
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  58.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(8-nonenyl)-3,7-dimethylxanthine 在 硫酸 作用下， 以 水 为溶剂， 生成 1-(8-hydroxynonyl)-3,7-dimethylxanthine
  参考文献：
  名称：

  Substituted long chain alcohol xanthine compounds

  摘要：

  本发明涉及化合物和制药组合物，其包括以下结构的化合物：##STR1## 其中一个或两个R中的每一个独立地是##STR2## 其中n是从7到20的整数，X或Y中至少一个是--OH，如果X或Y中的一个是--OH，则另一个X或Y是H，CH.sub.3，CH.sub.3 --CH.sub.2，CH.sub.3 --(CH.sub.2).sub.2 --或(CH.sub.3).sub.2 --CH.sub.2 --，W.sub.1，W.sub.2和W.sub.3独立地是H，CH.sub.3，CH.sub.3 --CH.sub.2，CH.sub.3 --(CH.sub.2).sub.2 --或(CH.sub.3).sub.2 --CH.sub.2 --，其中烷基基团可以被羟基，卤素或二甲氨基基团取代和/或由氧原子，H或烷基（1-4C）中断，包括已分离的对映异构体和/或二面体异构体，盐和混合物。特别地，这些化合物在主要刺激和它们与细胞接触的几秒钟内降低了源自所述PA的不饱和非花生四烯酸磷脂酸（PA）和二酰基甘油（DAG）的升高水平。调节作用取决于目标细胞的性质和施加的刺激。

  公开号：

  US05473070A1
• 作为产物：
  描述：

  8-壬烯-1-醇 在 NaH 、 三乙胺 作用下， 以 二氯甲烷 、 水 、 二甲基亚砜 、 mineral oil 为溶剂， 生成 1-(8-nonenyl)-3,7-dimethylxanthine
  参考文献：
  名称：

  Substituted long chain alcohol xanthine compounds

  摘要：

  本发明涉及化合物和制药组合物，其包括以下结构的化合物：##STR1## 其中一个或两个R中的每一个独立地是##STR2## 其中n是从7到20的整数，X或Y中至少一个是--OH，如果X或Y中的一个是--OH，则另一个X或Y是H，CH.sub.3，CH.sub.3 --CH.sub.2，CH.sub.3 --(CH.sub.2).sub.2 --或(CH.sub.3).sub.2 --CH.sub.2 --，W.sub.1，W.sub.2和W.sub.3独立地是H，CH.sub.3，CH.sub.3 --CH.sub.2，CH.sub.3 --(CH.sub.2).sub.2 --或(CH.sub.3).sub.2 --CH.sub.2 --，其中烷基基团可以被羟基，卤素或二甲氨基基团取代和/或由氧原子，H或烷基（1-4C）中断，包括已分离的对映异构体和/或二面体异构体，盐和混合物。特别地，这些化合物在主要刺激和它们与细胞接触的几秒钟内降低了源自所述PA的不饱和非花生四烯酸磷脂酸（PA）和二酰基甘油（DAG）的升高水平。调节作用取决于目标细胞的性质和施加的刺激。

  公开号：

  US05473070A1

文献信息

• Cell signaling inhibitors
  申请人：Cell Therapeutics, Inc.

  公开号：US05470878A1

  公开（公告）日：1995-11-28

  Therapeutic compounds have the formula: (X)j-(non-cyclic core moiety), j being an integer from one to three, the core moiety is non-cyclic and X is a racemic mixture, R or S enantiomer, solvate, hydrate, or salt of: ##STR1## *C is a chiral carbon atom, n is an integer from one to four (preferably from one to three), one or more carbon atoms of (CH.sub.2).sub.n may be substituted by a keto or hydroxy group, and m is an integer from one to fourteen. Independently, R.sub.1 and R.sub.2 may be a hydrogen, a straight or branched chain alkane or alkene of up to twelve carbon atoms in length, or --(CH.sub.2).sub.w R.sub.5, w being an integer from two to fourteen and R.sub.5 being a mono-, di- or tri-substituted or unsubstituted aryl group, substituents on R.sub.5 being hydroxy, chloro, fluoro, bromo, or C.sub.1-6 alkoxy. Or jointly, R.sub.1 and R.sub.2 form a substituted or unsubstituted, saturated or unsaturated heterocyclic group having from four to eight carbon atoms, N being a hetero atom. R.sub.3 is a hydrogen or C.sub.1-3. Or, therapeutic compounds may also have the formula: ##STR2## R.sub.4 is a hydrogen, a straight or branched chain alkane or alkene of up to eight carbon atoms in length, --(CH.sub.2).sub.w R.sub.5, w being an integer from two to fourteen and R.sub.5 being a mono-, di- or tri-substituted or unsubstituted aryl group, substituents on R.sub.5 being hydroxy, chloro, fluoro, bromo, or C.sub.1-6 alkoxy, or a substituted or unsubstituted, saturated or unsaturated heterocyclic group having from four to eight carbon atoms. r and s are independently integers from one to four, the sum (r+s) not being greater than five. t is an integer from one to fourteen and one or more carbon atoms of (CH.sub.2).sub.s or (CH.sub.2).sub.t may be substituted by a keto or hydroxy group.

  治疗性化合物的化学式为：(X)j-(非环核心基团)，其中j为1到3之间的整数，核心基团为非环状，X为一个消旋混合物、R或S对映体、溶剂化合物、水合物或盐类：*C为手性碳原子，n为1到4之间的整数（最好为1到3），(CH.sub.2).sub.n的一个或多个碳原子可被酮基或羟基取代，m为1到14之间的整数。独立地，R.sub.1和R.sub.2可以是氢、直链或支链烷烯链，长度最多为12个碳原子，或--(CH.sub.2).sub.w R.sub.5，其中w为2到14之间的整数，R.sub.5为单取代、双取代或三取代的芳基基团，R.sub.5上的取代基为羟基、氯、氟、溴或C.sub.1-6烷氧基。或者，R.sub.1和R.sub.2共同形成一个取代或未取代、饱和或不饱和的杂环基团，含有4到8个碳原子，N为杂原子。R.sub.3为氢或C.sub.1-3。或者，治疗性化合物也可以具有以下化学式：R.sub.4为氢、直链或支链烷烯链，长度最多为8个碳原子，--(CH.sub.2).sub.w R.sub.5，其中w为2到14之间的整数，R.sub.5为单取代、双取代或三取代的芳基基团，R.sub.5上的取代基为羟基、氯、氟、溴或C.sub.1-6烷氧基，或者为一个取代或未取代、饱和或不饱和的含有4到8个碳原子的杂环基团。r和s独立地为1到4之间的整数，和不大于5。t为1到14之间的整数，(CH.sub.2).sub.s或(CH.sub.2).sub.t的一个或多个碳原子可被酮基或羟基取代。
• Olefin substituted long chain compounds
  申请人：Cell Therapeutics, Inc.

  公开号：US05521315A1

  公开（公告）日：1996-05-28

  There is disclosed an olefin-substituted compound having the formula: R--(core moiety), wherein R is a straignt chain hydrocarbon having at least one double bond and a carbon chain length of from about 6 to about 18 carbon atoms, wherein multiple double bonds are separated from each other by at least three carbon atoms, wherein the closest double bond to the core moiety is at least five carbon atoms from the core moiety, and wherein the hydrocarbon chain may be substituted by a hydroxyl, halo, keto or dimethylanimo group and/or interrupted by an oxygen atom and salts thereof and pharmaceutical compositions thereof.

  公开了一种具有以下结构的烯烃取代化合物：R--（核心基团），其中R是直链碳氢化合物，具有至少一个双键，碳链长度约为6至18个碳原子，多个双键之间至少相隔三个碳原子，最接近核心基团的双键距离核心基团至少五个碳原子，碳氢链可能被羟基、卤素、酮基或二甲氨基基团取代和/或由氧原子中断，以及其盐和药物组合物。
• Substituted amino alcohol compounds
  申请人：Cell Therapeutics, Inc.

  公开号：US05641783A1

  公开（公告）日：1997-06-24

  Disclosed are compounds having a straight or branched aliphatic hydrocarbon structure of formula I: ##STR1## In formula I, n is an integer from one to four and m is an integer from four to twenty. Independently, R.sub.1 and R.sub.2 are hydrogen, a straight or branched chain alkyl, alkenyl or alkynyl of up to twenty carbon atoms in length or --(CH.sub.2).sub.w R.sub.5. If R.sub.1 or R.sub.2 is --(CH.sub.2).sub.w R.sub.5, w may be an integer from one to twenty and R.sub.5 may be an hydroxyl, halo, C.sub.1-8 alkoxyl group or a substituted or unsubstituted carbocycle or heterocycle. Alternatively, R.sub.1 and R.sub.2 may jointly form a substituted or unsubstituted, saturated or unsaturated heterocycle having from four to eight carbon atoms, N being a hetero atom of the resulting heterocycle. R.sub.3 may be either hydrogen or C.sub.1-3. In the compounds, a total sum of carbon atoms comprising R.sub.1 or R.sub.2, (CH.sub.2).sub.n and (CH.sub.2).sub.m does not exceed forty. R.sub.4 is a terminal moiety comprising a substituted or unsubstituted, oxidized or reduced ring system, the ring system having a single ring or two to three fused rings, a ring comprising from three to seven ring atoms. The disclosed compounds are effective agents to inhibit undesirable responses to cell stimuli.

  本文揭示了具有公式I的直链或支链脂肪烃结构的化合物：##STR1## 在公式I中，n是一个从一到四的整数，m是一个从四到二十的整数。独立地，R.sub.1和R.sub.2是氢，长度最多为二十个碳原子的直链或支链烷基，烯基或炔基，或者是--(CH.sub.2).sub.w R.sub.5。如果R.sub.1或R.sub.2是--(CH.sub.2).sub.w R.sub.5，w可以是一个从一到二十的整数，R.sub.5可以是一个羟基，卤素，C.sub.1-8烷氧基团或一个取代或未取代的碳环或杂环。另外，R.sub.1和R.sub.2可以共同形成一个取代或未取代的，饱和或不饱和的，由四到八个碳原子组成的杂环，N是所得杂环的杂原子。R.sub.3可以是氢或C.sub.1-3。在化合物中，包括R.sub.1或R.sub.2，(CH.sub.2).sub.n和(CH.sub.2).sub.m的碳原子总和不超过四十。R.sub.4是一个末端基团，包括一个取代或未取代的，氧化或还原的环系统，该环系统具有单环或两到三个融合环，一个环包含三到七个环原子。所述化合物是有效的抑制细胞刺激引起的不良反应的药剂。
• Amino-alcohol substituted cyclic compounds
  申请人：Cell Therapeutics, Inc.

  公开号：US05837703A1

  公开（公告）日：1998-11-17

  Therapeutic compounds have the formula: (X)j-(core moiety), j being an integer from one to three, the core moiety comprising a core moiety, the core moiety being a heterocycle having one ring or two-fused rings, each ring having five or six ring atoms, A being a carbon atom of the core moiety and attached to a terminal carbon atom of (CH.sub.2).sub.m, and X has a structure and X being a racemic mixture, R or S enantiomer, solvate, hydrate, or salt of: ##STR1## *C is a chiral carbon atom, n is an integer from one to four (preferably from one to three), one or more carbon atoms of (CH.sub.2).sub.n may be substituted by a keto or hydroxy group, and m is an integer from one to fourteen. Independently, R.sub.1 and R.sub.2 may be a hydrogen, a straight or branched chain alkyl or alkenyl of up to twelve carbon atoms in length, or --(CH.sub.2).sub.w R.sub.5, w being an integer from two to fourteen and R.sub.5 being a mono-, di- or tri-substituted or unsubstituted aryl group, substituents on R.sub.5 being hydroxy, chloro, fluoro, bromo, or C.sub.1-6 alkoxyl. Or jointly, R.sub.1 and R.sub.2 form a substituted or unsubstituted, saturated or unsaturated heterocyclic group having from four to eight carbon atoms, N being a hetero atom. R.sub.3 is a hydrogen or C.sub.1-3. Or, therapeutic compounds may also have the formula: ##STR2## R.sub.4 is a hydrogen, a straight or branched chain alkyl or alkenyl of up to eight carbon atoms in length, --(CH.sub.2).sub.w R.sub.5, w being an integer from two to fourteen and R.sub.5 being a mono-, di- or tri-substituted or unsubstituted aryl group, substituents on R.sub.5 being hydroxy, chloro, fluoro, bromo, or C.sub.1-6 alkoxyl, or a substituted or unsubstituted, saturated or unsaturated heterocyclic group having from four to eight carbon atoms, r and s are independently integers from one to four, the sum (r+s) not being greater than five. t is an integer from one to fourteen and one or more carbon atoms of (CH.sub.2).sub.s or (CH.sub.2).sub.t may be substituted by a keto or hydroxyl group.

  治疗化合物的公式为：(X)j-(核心基团)，其中j为从一到三的整数，核心基团包括一个杂环，该杂环具有一个环或两个融合的环，每个环有五个或六个环原子，A是核心基团的碳原子，连接到(CH.sub.2).sub.m的末端碳原子，而X具有结构，X是一个外消旋体混合物，R或S对映体，溶剂化物，水合物或盐，其结构如下：##STR1## *C是一个手性碳原子，n是从一到四的整数（最好从一到三），(CH.sub.2).sub.n中的一个或多个碳原子可能被酮基或羟基取代，m是从一到十四的整数。独立地，R.sub.1和R.sub.2可以是氢，长度为最多十二个碳原子的直链或支链烷基或烯基，或--(CH.sub.2).sub.w R.sub.5，其中w是从二到十四的整数，R.sub.5是一个单取代，二取代或三取代或未取代的芳基，R.sub.5上的取代基是羟基，氯，氟，溴或C.sub.1-6烷氧基。或共同地，R.sub.1和R.sub.2形成一个取代或未取代的，饱和或不饱和的杂环基团，其碳原子数为四到八，N是一个杂原子。R.sub.3是氢或C.sub.1-3。或者，治疗化合物也可以具有以下公式：##STR2## R.sub.4是氢，长度为最多八个碳原子的直链或支链烷基或烯基，--(CH.sub.2).sub.w R.sub.5，其中w是从二到十四的整数，R.sub.5是一个单取代，二取代或三取代或未取代的芳基，R.sub.5上的取代基是羟基，氯，氟，溴或C.sub.1-6烷氧基，或一个取代或未取代的，饱和或不饱和的杂环基团，其碳原子数为四到八，r和s是独立的从一到四的整数，其和（r+s）不大于五。t是从一到十四的整数，(CH.sub.2).sub.s或(CH.sub.2).sub.t中的一个或多个碳原子可能被酮基或羟基取代。
• Olefin-substituted long chain xanthine compounds
  申请人：Cell Therapeutics, Inc.

  公开号：US05354756A1

  公开（公告）日：1994-10-11

  There is disclosed compounds and pharmaceutical compositions having a xanthine core and one or two hydrocarbon side chains bonded to a ring nitrogen atom, wherein the hydrocarbon side chains are independently a straight chain hydrocarbon having at least one double bond in a carbon chain length of from about 4 to about 18 carbon atoms in length, wherein multiple double bonds are separated from each other by at least three carbon atoms, and wherein the hydrocarbon chain may be substituted by a hydroxyl, halo or dimethylamino group and/or interrupted by an oxygen atom. The compounds lower elevated levels of unsaturated, non-arachidonate phosphatidic acid (PA) and diacylglycerol (DAG) derived from said PA within seconds of the primary stimulus and their contact with cells. The modulatory effect depends on the nature of the target cell and the stimulus applied.

  本发明涉及具有黄嘌呤核心和一个或两个碳氢侧链与环氮原子结合的化合物和制药组合物，其中碳氢侧链是独立的直链碳氢化合物，其在碳链长度为大约4到大约18的长度范围内至少有一个双键，其中多个双键相互间隔至少三个碳原子，并且碳氢侧链可以被羟基，卤素或二甲基氨基基团取代和/或由氧原子中断。该化合物在与细胞接触后，可以在几秒钟内降低非花生四烯酸磷脂酸（PA）和二酰基甘油（DAG）的升高水平。其调节效应取决于靶细胞的性质和刺激的应用。